Jubilant Life Sciences has reported results for third quarter ended December 31, 2014.
The company has reported a net loss of Rs 8.48 crore for the quarter under review as compared to a net profit of Rs 164.52 crore for the same quarter in the previous year. Total income of the company has decreased by 22.58% at Rs 741.19 crore for Q3FY15 as compared Rs 957.41 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a net loss of Rs 11.16 crore for the Q3 FY15 as compared to a net profit of Rs 143.43 crore in Q3 FY14. However, total income increased 0.21% to Rs 1451.53 crore in the quarter under review as compared to Rs 1448.49 crore in the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: